Veranova

Curious about targeted therapies? Veranova's Vice President and General Manager, Lucas Sauer-Jones, recently spoke to International Pharmaceutical Industry Journal about the vital role of contract development and manufacturing organizations (#CDMOs) in highly potent API (#HPAPI) development. Read the full article here: https://lnkd.in/grB8KyEr

Don’t miss Veranova’s CEO Mike Riley, at Fierce JPM Week 2025 (Fierce Life Sciences Events)! As part of a novel collaboration with David Shrier, CEO of Phorum.AI, Mike will discuss how #AI can accelerate innovation in #pharma on January 14 at 8.40am PST. Register now: https://lnkd.in/gZyhynYf

Veranova is a #CDMO that manages complexity with confidence. Our world-leading technologies and technical expertise enable us to tackle the most difficult #DrugDevelopment challenges and produce life-changing therapeutics for patients in need. Watch our new video to learn more: https://lnkd.in/g5sGskNk

Did you know Veranova has experience in the development and production of PEGylated molecules and synthetic lipids? Alongside our comprehensive expertise in ADCs and other drug-conjugate polymers, we can also provide unique stabilization and purification techniques to improve efficiency, cost, and quality for flexible molecule production. Visit our PEGs and lipids webpage to learn more: https://lnkd.in/dJNAA6du

At Veranova, we are proud that more than 35% of our scientific staff have been part of our team for over five years. We believe that this reflects our commitment to creating an environment where our team feels valued, empowered, and encouraged to succeed every day. Learn more about working at Veranova and view our current vacancies here: https://lnkd.in/ee3qPxZP

We are excited to announce that the Veranova team will be in San Francisco, CA from January 14-15 to attend Fierce JPM Week 2025 (Fierce Life Sciences Events). Are you also attending? If so, visit our experts to find out how we can help you overcome complexity and accelerate your innovation.

Our New England Team recently held their annual food drive competition, collecting just over 1,100 pounds of food to donate to their neighboring food pantry, Loaves and Fishes! Chemical Development and Analytical took the lead, donating just over 600 pounds, but we are grateful to everyone who made time to give back this holiday season.

Parallel solid form screening and physicochemical profiling can provide significant benefits, helping researchers understand the polymorphism of their API and identify the most suitable solid form as early as possible during development. In our latest white paper, Veranova’s Associate Director, Pharmorphix® Solid Form & Particle Engineering, Olana Couzins, explores the relationship between solid form properties and physicochemical characteristics. Olana also explains how these disciplines can be most effectively integrated to streamline development and accelerate commercialization. Download to learn more:https://lnkd.in/g7q6MWMZ

Over the last few months, we have really enjoyed highlighting the work of our Pharmorphix team and providing insight into some of the complex API challenges they have solved for our clients. In this year’s last #PharmorphixFix post, Veranova’s Senior Scientist, Ruth Lunt, explains how the team helped a client optimize their crystallization process to improve API manufacturing. Find out below how the Phamorphix team combined its extensive solid form and particle engineering knowledge with industry-leading process analytical technology to redesign the client’s process and achieve a successful project outcome. Make sure to keep an eye out in the new year for more #PharmorphixFix posts and, in the meantime, visit our website to learn more about how our team’s expertise and capabilities can help you accelerate early drug development: https://veranova.com

Last month at CPHI Milan, Veranova’s Chief Commercial Officer, Cécile Maupas, and Chief Technology Officer, Rohtash Kumar, sat down with 24/7 Biopharma (Ellie Bruni) to discuss our commitment to helping customers navigate the increasing complexity of drug development and manufacturing. Watch the full interview here: https://lnkd.in/g-if-Rn8